Home/Filings/4/0001628280-23-031389
4//SEC Filing

Arbet-Engels Christophe 4

Accession 0001628280-23-031389

CIK 0001501697other

Filed

Sep 4, 8:00 PM ET

Accepted

Sep 5, 4:15 PM ET

Size

5.6 KB

Accession

0001628280-23-031389

Insider Transaction Report

Form 4
Period: 2023-08-31
Arbet-Engels Christophe
Chief Medical Officer
Transactions
  • Award

    Stock Option (right to buy)

    2023-08-31$1.28/sh+1,250,000$1,600,0001,250,000 total
    Exercise: $1.28Exp: 2033-08-30Common Stock (1,250,000 underlying)
Footnotes (1)
  • [F1]25% of the shares subject to the option shall vest on August 31, 2024, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date.

Issuer

X4 Pharmaceuticals, Inc

CIK 0001501697

Entity typeother

Related Parties

1
  • filerCIK 0001802615

Filing Metadata

Form type
4
Filed
Sep 4, 8:00 PM ET
Accepted
Sep 5, 4:15 PM ET
Size
5.6 KB